Stereotactic image-guided lung radiotherapy (SBRT) for clinical early-stage NSCLC: A long-term report from a multi-institutional database of patients treated with or without a pathologic diagnosis.
Early stage lung cancer is treated with stereotactic body radiotherapy (SBRT) in patients unfit or unwilling to undergo surgical resection. Some patients' comorbidities are so severe that they are unable to even undergo biopsy. Clinical diagnosis without biopsy before SBRT has been utilized, but there are limited data on its efficacy. Data on patients treated with SBRT for non-small cell lung cancer (NSCLC), with and without tissue confirmation, were collected from multiple institutions across Europe, Canada, and the United States. Patients with a minimum of two years of comprehensive follow up were selected for analysis. Treatment and patient characteristics were compared. Overall survival (OS), disease-free survival (DFS), cause-specific survival (CSS), rates of local recurrence (LR), regional recurrence (RR), and distant metastasis (DM) were calculated and analyzed. Seven hundred one patients were identified, of which 67% had tissue confirmation of their tumors. OS, CSS, and DFS three and five-year outcomes were 83.8%, 93.1%, 69%, and 60.6%, 86.7%, 45.5%, respectively. LR, RR, and DM rates at three and five-years were 6.4%, 9.3%, 14.3%, and 10.5%, 14.3%, 19.7%, respectively. There were no statistically significant differences in survival outcomes or recurrences between the biopsy and no biopsy cohorts. SBRT for clinically diagnosed lung cancers is efficacious in appropriately selected patients, with similar outcomes as those with pathologic diagnosis. Thorough clinical and radiographic evaluation in a multidisciplinary setting is critical to the management of these patients.